Subjective experience with antipsychotics: Quantitative evaluation;La experiencia subjetiva con antipsicóticos: Evaluación cuantitativa

Actas Espanolas de Psiquiatria

Volumn 34, Issue 5, 2006, Pages 287-294

  Barberá, Maria ^a   Sanjuan J ^b   Munarriz M ^c   Novella, E ^b   Santiago, C ^c   Simo M ^c  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c Centra de Salud Mental de Burriana   (Spain)

Author keywords

Antipsychotis; Psychosis; Rating Scales; Schizophrenia; Side effects; Subjective experience

Indexed keywords

NEUROLEPTIC AGENT;

ARTICLE; HUMAN; PATIENT SATISFACTION; QUESTIONNAIRE;

ANTIPSYCHOTIC AGENTS; HUMANS; PATIENT SATISFACTION; QUESTIONNAIRES;

EID: 33750508170     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol 1995;10(Suppl. 3):133-8.
2. Singh MM. Dysphoric response to neuroleptic treatment in schizophrenia and its prognostic significance. Dis Nerv Syst 1976;37:191-6.
3. Hogan TP, Awad AG, Eastwood MR. Early subjective response and prediction of outcome to neuroleptic drug therapy in schizophrenia. Can J Psychiatry 1985;30:246-8.
4. Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res 2000;24:241-7.
5. Kampman O, Lehtinen K, Lassila V, Leinonen E, Poutanen O, Koivisto AM. Attitudes towards neuroleptic treatment: reliability and validity of the attitudes towards neuroleptic treatment (ANT) questionnaire. Schizophr Res 2000;45:223-34.
6. Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophr Bull 1993;19:609-18.
7. Naber D, Moritz S, Lambert M, Pajonk FG, Holzbach R, Mass R, et al. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res 2001;50:79-88.
8. Van Putten T, May PR. Subjective response as a predictor of outcome in pharmacotherapy: the consumer has a point. Arch Gen Psychiatry 1978;35:477-80.
9. Van Putten T, May PR, Jenden DJ, Cho AK, Yale C. Plasma and saliva levels of chlorpromazine and subjective response. Am J Psychiatry 1980;137:1241-2.
10. Van Putten T, May PR, Marder SR. Subjective responses to thiothixene and chlorpromazine. Psychopharmacol Bull 1980;16:36-8.
11. Van Putten T, May PR, Marder SR, Wittmann IA. Subjective response to antipsychotic drugs. Arch Gen Psychiatry 1981;38:187-90.
12. Singh MM, Kay SR. Dysphoric Response to Neuroleptic Treatment in Schizophrenia: its relationship to Autonomic Arousal and Prognosis. Biol Psychiatry 1979;14:277-94.
13. Van Putten T. Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 1974;31:67-72.
14. Hogan TP, Awad AG, Eastwood R. A self report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983;13:177-83.
15. Hogan TP, Awad AG. Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures. Psychol Med 1992;22:347-52.
16. Barofsky I. Behavioral therapeutics and the management of therapeutics regimens. En: Sackett DL, Haynes RB, editores. Compliance with therapeutic regimens. Baltimore: John Hopkins University Press, 1976; p. 100-9.
17. Awad AG, Hogan TP. Subjective response to neuroleptics and the quality of life: implications for treatment outcome. Acta Psychiatr Scand 1994;380(Suppl.):27-32.
18. Awad AG, Hogan TP, Voruganti LN, Heslegrave RJ. Patients' subjective experiences on antipsychotic medications: implications for outcome and quality of life. Int Clin Psychopharmacol 1995;10(Suppl. 3):123-32.
19. Awad AG, Voruganti LN, Heslegrave RJ, Hogan TP. Assessment of the patient's subjective experience in acute neuroleptic treatment: implications for compliance and outcome. Int Clin Psychopharmacol 1996;11(Suppl. 2):55-9.
20. Awad AG, Voruganti LNP, Heslegrave RJ. A conceptual model of quality of life in schizophrenia: description and preliminary clinical validation. Qual life Res 1997;6:21-6.
21. Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, Zirul S, Awad A. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res 2000;43:135-45.
22. Hofer A, Kemmler G, Eder U, Honeder M, Hummer M, Fleischhacker WW. Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia. J Clin Psychiatry 2002;63:49-53.
23. Voruganti L, Cortese L, Owyeumi L, Kotteda V, Cernovsky Z, Zirul S, et al. Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr Res 2002;57:201-8.
24. Voruganti L, Slomka P, Zabel P, Costa G, So A, Matter A, et al. Subjective effects of AMPT-induced dopamine depletion in schizophrenia: correlation between dysphoric responses and striatal D(2) binding ratios on SPECT imaging. Neuropsychopharmacology 2001;25:642-50.
25. Voruganti LN, Awad AG. Personal evaluation of transitions in treatment (PETiT): a scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia. Schizophr Res 2002;56:37-46.
26. Weiden PJ, Mann JJ, Dixon L, Haas G, DeChillo N, Frances AJ. Is neuroleptic dysphoria a healthy response? Compr Psychiatry 1989;30:546-52.
27. Weiden PJ, Rapkin B, Mott T, Zygmunt A, Goldman D, Horvitz-Lennon M, et al. Rating of medication influences (ROMI) scale in schizophrenia. Schizophr Bull 1994;20:297-310.
28. Weiden PJ, Rapkin B, Zygmunt A, Mott T, Goldman D, Frances A. Postdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen. Psychiatr Serv 1995;46:1049-54.
29. Weiden PJ, Aquila R, Emanuel M, Zygmunt A. Long-term considerations after switching antipsychotics. J Clin Psychiatry 1998;59(Suppl. 19):36-49.
30. Weiden PJ, Mott T, Curcio N. Recognition and management of neuroleptic noncompliance. En: Shirqui C, Nasrallah H, editores. Contemporary Issues in the treatment of schizophrenia. Washington: American Psychiatric Association Press, 1995; p. 411-34.
31. Liddle PF, Barnes TR. The subjective experience of deficits in schizophrenia. Comparative Psychiatry 1988;29:157-64.
32. Windgassen K. Treatment with neuroleptics: the patient's perspective. Acta Psychiatr Scand 1992;86:405-10.
33. Lader M. Neurolpeptic induced deficit syndrome: old problem, new challenge. J Psychopharmacol 1993;7:392-3.
34. Lewander T. Neuroleptics and the neuroleptic-induced deficit syndrome. Acta Psychiatr Scand Suppl 1994;380:8-13.
35. De Haan L, Lavalaye J, Linszen D, Dingemans PM, Booij J. Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. Am J Psychiatry 2000;157:1019-20.
36. De Haan L, Weisfelt M, Dingemans PM, Linszen DH, Wouters L. Psychometric properties of the Subjective Well-Being Under Neuroleptics scale and the Subjective Deficit Syndrome Scale. Psychopharmacology 2002;162:24-8.
37. De Haan L, Van Bruggen M, Lavalaye J, Booij J, Dingemans PM, Linszen D. Subjective experience and d(2) receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. Am J Psychiatry 2003;160:303-9.
38. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self reported measure of medication adherence. Med Care 1986;24:67-74.
39. Voruganti L, Awad AG. Neuroleptic dysphoria: towards a new synthesis. Psychopharmacology 2004;171:121-32.
40. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology and pharmacology in schizophrenia. Am J Psychiatry 2003;160:13-23.